What's breaking now, across thousands of outlets.
Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said its drug divesiran met the primary endpoint in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
Ticks are especially abundant this summer. However, there are several ways to mitigate the risks associated with them, says Tiina Elvisto, associate professor of plant ecology at Tallinn University.
Dubai: A health awareness programme held in Dubai has highlighted the importance of preventive healthcare, regular medical check-ups and early intervention, particularly for people whose busy work…
Journalists can apply for AHF Nigeria’s two-month HIV and TB media reporting project to promote ethical, solutions-focused reporting on these diseases.
A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.
Nigeria’s healthcare sector needs more than additional funding to expand. The post FCMB, Healthcare Stakeholders Set Out Roadmap to Move Nigeria’s Health Sector from Survival to Scale appeared first…
